The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. - Wikidata - awgldk - TriplyDB

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

http://www.wikidata.org/entity/Q42278556

about

Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy.Global response to HIV: treatment as prevention, or treatment for treatment?Update on opportunistic infections in the era of effective antiretroviral therapy Can early therapy reduce inflammation?Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.Treatment as prevention--where next?Antiretroviral therapy: when to start Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons.Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes.Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study Opportunistic Infections in HIV-Infected Patients Differ Strongly in Frequencies and Spectra between Patients with Low CD4+ Cell Counts Examined Postmortem and Compensated Patients Examined Antemortem Irrespective of the HAART Era.Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.Bloodstream infections in HIV-infected patients.Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy T cell susceptibility to HIV influences outcome of opportunistic infections.Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration Update on antiretroviral treatment during primary HIV infection.Management of drug resistantTB in patients with HIV co-infection.Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.CD4 cell count at initiation of ART, long-term likelihood of achieving CD4 >750 cells/mm3 and mortality risk.Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course.Severe Paracoccidioidomycosis in a 14-Year-Old Boy.Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status.Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety.The case for viral load testing in adolescents in resource-limited settings.Modelling the cost-effectiveness of HIV care shows a clear benefit when transmission risk is considered in the calculations - A message for Central and Eastern Europe.Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study.

P2860

Q28538165-3DC013EA-6E80-4422-BC71-36A7E412A85E Q33593774-23E14CE1-BDCA-4F86-B96C-BDFCECAE72FC Q33834625-2B94F366-F60E-43F6-850C-4963816DC889 Q34077723-BECFD4C9-83AF-4097-96FA-C3E760C3DFD8 Q34085853-48902574-EAF2-4B11-9D48-3ADF4D5A472E Q34159822-4BC053C7-2217-4B11-A9D1-09DD3D93A808 Q34379806-E462622F-57F0-4AA9-930A-2059E8F86F7A Q34485916-CEC31F9C-7D09-47B8-99DB-17FA556488A3 Q34666498-4FFDC6A1-50C0-40C3-81E5-37C49FB8021F Q34718341-4104EE3D-2238-4335-93FD-AED76F6B89A3 Q35204279-B9824E7E-7C58-4E6A-9D89-0E353711A529 Q35338750-4B5CF279-3EAE-4B9A-BAD5-ED3533AA0535 Q35576220-2CCDCE83-1128-40C1-BE5A-02416CB603CC Q35620368-8C1E3A86-6CFD-4A67-B834-039F7E5E2736 Q35894666-5E56ECDB-9288-41E9-8D98-9C910FFBBCB9 Q36047903-0F579ACD-3CE2-4D4A-B1EA-6677C9707B8E Q36068935-56F8C181-3542-4098-B132-2C8CB27CFE17 Q36128189-90968C5C-E04B-41BC-A2E6-616C1C53823B Q36783202-13BD62BB-558C-4DC5-B646-CA5C2CEC3572 Q36913307-CDF82EF1-E51C-4DD8-A399-54F314E272E0 Q37104112-B84E0127-4042-47AF-977F-684BAC8C57E2 Q37382387-D4D6D8F4-32F8-422F-A741-0B910E2AB274 Q37490654-1FA415AC-21DF-4B5F-B11B-E5E14EC9EE68 Q38209874-18CCA946-5304-47D7-A8DB-F66F71537311 Q38610637-6819EFCE-CFE2-4CB2-A3D5-F6CFADD98F77 Q38759954-5AC2A437-3C31-4179-80B7-68AEAD76B4C5 Q38917930-A1A47EF5-1D5F-416A-A43D-C6815D0D5F95 Q39455493-00B4AEC3-3051-4FC8-B7BF-262E257FF235 Q39665419-FF48AE1B-6B58-45F4-8684-6B6B0577A04F Q40250347-09A06D0C-87B6-4E40-B160-1191EF869972 Q40444741-641FD148-15C3-4D1D-B32D-B1E56A303A0D Q40540273-9C7F125C-4752-4C3A-9856-6D3885692CAA Q40629624-926704EF-2F99-4BA5-9B18-5937C1D67AE2 Q40979736-2D4DA396-E425-407E-8D99-7854C5D7DD35 Q41333604-EDCC9DF9-4E82-45F5-92C2-F69EC27586DA Q46391416-54DF00AA-F234-430C-8EE8-EBFA23CB1D5A Q47141254-F3D704EA-D52A-493C-8F95-5E0EB1B268F1 Q53068032-D3C78297-4743-4929-9B4A-A1FB67A16434

P2860

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

http://www.wikidata.org/entity/Q42278556

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

The incidence of AIDS-defining ...... on antiretroviral therapy era.

@en

The incidence of AIDS-defining ...... on antiretroviral therapy era.

@nl

type

label

The incidence of AIDS-defining ...... on antiretroviral therapy era.

@en

The incidence of AIDS-defining ...... on antiretroviral therapy era.

@nl

prefLabel

The incidence of AIDS-defining ...... on antiretroviral therapy era.

@en

The incidence of AIDS-defining ...... on antiretroviral therapy era.

@nl

P1433

Q42278556-0E113D9F-6BBD-467B-BAD2-B9ACF5BB810B

P1476

Q42278556-38196EA6-3E97-4792-B14B-11D8691D3A58

P2093

Q42278556-0402E919-FA1B-46E0-A86F-9AF1DC73BA27

Q42278556-0920C447-B531-4F55-9842-05B139A90BB2

Q42278556-1F82F910-893F-4004-9E21-82BDC3725EE1

Q42278556-21C538AE-334A-410E-8E1A-18C935C3AE7D

Q42278556-27838591-56F6-4F9B-BFD9-1D2356A251C4

Q42278556-29E2CB33-613F-470E-B1C8-1AFFE326D466

Q42278556-4E7E3416-ED2A-4099-A6A5-BBB39EF67DA0

Q42278556-4F23D6DE-1768-4A1D-B752-D238C2D2FB06

Q42278556-51B54518-B442-4147-8474-4FD45A00BE09

Q42278556-561015E3-4317-4965-AE41-478DF0258759

P2860

Q42278556-153B76BE-CBAD-45FA-B4D9-7A89908ACCE0

Q42278556-187647A1-A724-465C-B12F-A01712044AEF

Q42278556-191BE413-6A96-4A51-858E-A01D633A83CD

Q42278556-1A65A55B-CC09-493E-92C4-632188FF4C4E

Q42278556-1C1FA0A3-9968-476A-8EB1-E6BDCACA7C23

Q42278556-1EFE30E6-D798-44CE-86DC-8B80D69DE7A2

Q42278556-28214F2D-9D10-4DFD-8504-61DB99F38809

Q42278556-28323CC7-D5A4-4DB5-9208-7525CF570CC7

Q42278556-28B28A01-9333-4849-B91D-6EAC6A5A80C8

Q42278556-29154883-696A-4736-9780-3F020DF198B7

P304

Q42278556-2777B067-2D9F-477E-9402-CF5283E638C1

P31

Q42278556-AC75C923-7AFB-44A5-A13A-FFE553107C7C

P356

Q42278556-AA6C68DF-8D97-4EC6-B305-BF2E5673D53A

P407

Q42278556-831D251D-6F66-4979-9D08-AC0228948171

P433

Q42278556-5016723D-69DB-43FC-B99C-D7273F0EDC47

P478

Q42278556-23639801-EF3C-43A6-9C68-9491899792EB

P50

Q42278556-59DF0DB1-1055-4E1A-A3C7-E7089929E770

Q42278556-85769D59-6159-4FE2-892B-39EC6661EB80

Q42278556-A84042D1-152F-475F-96B2-0DC1E6B45982

Q42278556-EED41971-DF51-4A5B-A8FD-27E9DD34A18F

P577

Q42278556-4257DA3C-0ACA-43E3-A6A7-6DE5BD7EA3D7

P5875

Q42278556-85CE9768-4739-4912-AE2C-2ACF7BFFCD0A

P698

Q42278556-AC61BF38-F833-49E8-86F5-8094D5962525

P921

Q42278556-C189193C-5E07-4D41-BAA6-F856E2EAA385

P356

P1433

Clinical Infectious Diseases

P1476

The incidence of AIDS-defining ...... on antiretroviral therapy era.

@en

P2093

A Castagna

http://www.w3.org/2001/XMLSchema#string

A Mocroft

http://www.w3.org/2001/XMLSchema#string

A Papadopoulos

http://www.w3.org/2001/XMLSchema#string

A d'Arminio Monforte

http://www.w3.org/2001/XMLSchema#string

B Bartmeyer

http://www.w3.org/2001/XMLSchema#string

B Gazzard

http://www.w3.org/2001/XMLSchema#string

C Fabre-Colin

http://www.w3.org/2001/XMLSchema#string

C Mussini

http://www.w3.org/2001/XMLSchema#string

C Torti

http://www.w3.org/2001/XMLSchema#string

D Braun

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

CD4+ count-guided interruption of antiretroviral treatment

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion

AIDS across Europe, 1994-98: the EuroSIDA study.

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.

Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.

P304

1038-1047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIT423

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Geneviève Chêne

Pere Soler-Palacín

Robert Zangerle

P577

2013-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278395094

http://www.w3.org/2001/XMLSchema#string

P698

23921881

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug